ERES East Resources Acquisition Company

Top 10 Global Pharmaceutical Company Awards Three Thorough Phase I ECG Studies to eResearchTechnology for Cardiac Safety Monitoring and Information Distribution Services Studies Include More Than 38,000 ECGs for Later Stage Compounds in Three Therapeutic Areas; Trials to be Completed Before Year End PHILADELPHIA, June 17 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (eRT) (NASDAQ:ERES), a leading provider of centralized electrocardiographic (ECG) collection and interpretation services, announced today that it has been awarded three Thorough Phase I ECG studies totaling more than 38,000 ECGs from a top 10 global pharmaceutical organization under a previously executed Franchise agreement for three of its key drug candidates in clinical development. The agreements cover three extensive Phase I studies for which eRT is providing comprehensive support including the provision, training and ongoing assistance required for effective use of digital 12-lead Holter equipment designed to facilitate 24-hour digital recording of cardiac safety data that is subsequently provided to eRT for analysis. eRT will perform digital collection, measurement, interpretation, review, and distribution of cardiac safety data through its EXPeRT(R) workflow enabled data handling technology, the first solution in production that was designed explicitly to meet emerging international regulatory guidance and technical standards. "eRT's Franchise program, which was signed and implemented with this sponsor last year, has created a unique platform of enabling technology and available resources, complemented by continuous communications between the sponsor and eRT, which enables rapid response with the available capacity needed to support simultaneous execution of these thorough QT studies for later stage compounds nearing submission," said Scott Grisanti, senior vice president of business development and chief marketing officer at eRT. "eRT's scalable infrastructure supports delivery of the capacity and throughput required to support the simultaneous execution of these three studies in the coming months, along with numerous other Thorough Phase I ECG studies and hundreds of later phase trials. This ensures our customers, especially those in Franchise relationships, of the resources and expertise to address regulatory demands, accelerate development safely, and gain the competitive edge needed to deliver on their respective goals and objectives." Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com/) is a provider of technology and services to the pharmaceutical, biotechnology and medical device industries on a global basis. The company is a market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. The company is also a leader in providing technology and services to streamline the clinical trials process by enabling its customers to automate the collection, analysis, and distribution of clinical data in all phases of clinical development. Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. The sponsor may cancel these studies at its sole discretion. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the company's financial results can be found in the company's Reports on Forms 10-K and 10-Q filed with the Securities and Exchange Commission. DATASOURCE: eResearchTechnology, Inc. CONTACT: Joan Sterlacci of eResearchTechnology, Inc., +1-908-203-6473; or Matt Hayden of Hayden Communications, +1-858-456-4533, for eResearchTechnology Web site: http://www.ert.com/

Copyright